论文部分内容阅读
目的分析司来吉兰与左旋多巴二者联用治疗帕金森病运动障碍的临床疗效。方法 80例帕金森病运动障碍患者,按照随机数字法分成对照组和实验组,各40例。两组患者均给予基础治疗,在此基础上对照组患者采用左旋多巴片治疗,实验组患者采用司来吉兰联合左旋多巴片治疗。比较两组患者治疗前后统一帕金森氏病评分量表(UPDRS)评分、临床疗效及不良反应。结果治疗前两组患者UPDRS评分比较差异无统计学意义(P>0.05);治疗后2个月实验组患者UPDRS评分显著低于对照组,差异具有统计学意义(P<0.05)。实验组患者临床治疗总有效率为75.0%,显著高于对照组的40.0%,差异具有统计学意义(P<0.05)。治疗期间两组均没有出现显著不良反应。结论在对帕金森病运动障碍患者进行治疗时,联合应用司来吉兰和左旋多巴的治疗效果比较理想,具有临床应用价值。
Objective To analyze the clinical efficacy of selegiline and levodopa in the treatment of Parkinson’s disease dyskinesia. Methods Eighty patients with Parkinson’s disease and dyskinesia were divided into control group and experimental group according to random number method, 40 in each. Two groups of patients were given basic treatment, on the basis of the control group of patients treated with levodopa tablets, the experimental group of patients with selegiline plus levodopa tablets treatment. The UPDRS score, clinical efficacy and adverse reactions were compared between the two groups before and after treatment. Results There was no significant difference in UPDRS score between the two groups before treatment (P> 0.05). UPDRS score of experimental group was significantly lower than that of control group two months after treatment (P <0.05). The total effective rate of clinical trial was 75.0% in the experimental group, which was significantly higher than that in the control group (40.0%), the difference was statistically significant (P <0.05). No significant adverse reactions occurred in either group during treatment. Conclusion In the treatment of patients with Parkinson’s disease dyskinesia, the combination of selegiline and levodopa treatment is ideal and has clinical value.